Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy
Open Access
- 2 May 2007
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 7 (1), 37
- https://doi.org/10.1186/1471-2334-7-37
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and FailureThe Journal of Infectious Diseases, 2006
- Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatmentBMC Infectious Diseases, 2005
- Correlates of independent HIV-1 replication in the CNS and of its control by antiretroviralsNeurology, 2002
- Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence InstrumentsAIDS Care, 2000
- Cerebrospinal Fluid Viral Load, Intrathecal Immunoactivation, and Cerebrospinal Fluid Monocytic Cell Count in HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- A phase I/II trial of nimodipine for HIV-related neurologic complicationsNeurology, 1998
- Cerebrospinal Fluid Mononuclear Cell Counts Influence CSF HIV-1 RNA LevelsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- High Human Immunodeficiency Virus Type 1 RNA Load in the Cerebrospinal Fluid from Patients with Lymphocytic MeningitisThe Journal of Infectious Diseases, 1998
- Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndromeAnnals of Neurology, 1997
- Spectrum of Cerebrospinal Fluid Findings in Various Stages of Human Immunodeficiency Virus InfectionArchives of Neurology, 1988